Taxane resistance in prostate cancer is mediated by decreased drug-target engagement

Cabazitaxel is more active than first-generation taxanes in ABCB1(+) cell lines due to its reduced affinity for P-glycoprotein

(2018) George E. Duran et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Tuning microtubule dynamics to enhance cancer therapy by modulating FER-mediated CRMP2 phosphorylation

(2018) Yiyan Zheng et al.   Nature Communications

Cell death response to anti-mitotic drug treatment in cell culture, mouse tumor model and the clinic

(2017) Jue Shi et al.   ENDOCRINE-RELATED CANCER

The therapeutic potential of targeting ABC transporters to combat multi-drug resistance

(2017) Piyush Bugde et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naïve, Metastatic, Castration-Resistant Prostate Cancer

(2017) Emmanuel S. Antonarakis et al.   JOURNAL OF CLINICAL ONCOLOGY

LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease an­­d Serve as Models for Evaluating Cancer Therapeutics

(2017) Holly M. Nguyen et al.   PROSTATE

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

(2016) Nicholas D James et al.   LANCET

A Targetable GATA2-IGF2 Axis Confers Aggressiveness in Lethal Prostate Cancer

(2015) Samuel J. Vidal et al.   CANCER CELL

Inhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in Ovarian Cancer Cells by Stabilizing Microtubules

(2015) Yu Yu et al.   CANCER CELL

Novel Actions of Next-Generation Taxanes Benefit Advanced Stages of Prostate Cancer

(2015) R. de Leeuw et al.   CLINICAL CANCER RESEARCH

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer

(2015) Christopher J. Sweeney et al.   NEW ENGLAND JOURNAL OF MEDICINE

Androgen receptor splice variants circumvent AR blockade by microtubule-targeting agents

(2015) Guanyi Zhang et al.   Oncotarget

Androgen Receptor Splice Variants Determine Taxane Sensitivity in Prostate Cancer

(2014) Maria Thadani-Mulero et al.   CANCER RESEARCH

ERG induces taxane resistance in castration-resistant prostate cancer

(2014) Giuseppe Galletti et al.   Nature Communications

Preclinical Antitumor Activity of Cabazitaxel, a Semisynthetic Taxane Active in Taxane-Resistant Tumors

(2013) P. Vrignaud et al.   CLINICAL CANCER RESEARCH

Inhibition of ABCB1 Expression Overcomes Acquired Docetaxel Resistance in Prostate Cancer

(2013) Y. Zhu et al.   MOLECULAR CANCER THERAPEUTICS

Suppression of Acquired Docetaxel Resistance in Prostate Cancer through Depletion of Notch- and Hedgehog-Dependent Tumor-Initiating Cells

(2012) Josep Domingo-Domenech et al.   CANCER CELL

Androgen Receptor on the Move: Boarding the Microtubule Expressway to the Nucleus

(2012) M. Thadani-Mulero et al.   CANCER RESEARCH

Functional p53 determines docetaxel sensitivity in prostate cancer cells

(2012) Chengfei Liu et al.   PROSTATE

Taxane-Induced Blockade to Nuclear Accumulation of the Androgen Receptor Predicts Clinical Responses in Metastatic Prostate Cancer

(2011) M. S. Darshan et al.   CANCER RESEARCH

Mitosis is not a key target of microtubule agents in patient tumors

(2011) Edina Komlodi-Pasztor et al.   Nature Reviews Clinical Oncology

Tubulin-Targeting Chemotherapy Impairs Androgen Receptor Activity in Prostate Cancer

(2010) M.-L. Zhu et al.   CANCER RESEARCH

Induction of Clusterin by AKT--Role in Cytoprotection against Docetaxel in Prostate Tumor Cells

(2010) B. Zhong et al.   MOLECULAR CANCER THERAPEUTICS

Cancer Cells Display Profound Intra- and Interline Variation following Prolonged Exposure to Antimitotic Drugs

(2008) Karen E. Gascoigne et al.   CANCER CELL